by swisschambei in Business
Switzerland-based Alpex Pharma has signed a strategic cooperation agreement with the Chinese Pharma conglomerate Ban Loong Holdings. Ban Loong’s Chief Executive, Tang Ming recently visited Alpex Pharma to finalize and sign the partnership agreement with the Swiss company. The signing ceremony was attended by the President of Alpex Pharma, Kevin McKenzie, the CEO of Alpex Pharma, Shahbaz Ardalan, the Head of Research and Development, Gabriele Granata, and other prominent members.Ban Loong is a Hong Kong-based organization whose principal shareholders include Yunnan Baiyao Group Co. Ltd, one of China’s largest hybrid pharmaceutical and healthcare companies, and Shanghai Pharmaceuticals Group Co., which was the first company in China to get dual-listed by the Shanghai and Hong Kong Stock Exchanges. Last year, Shanghai Pharmaceutical, a Global Fortune 500 company, brought in Yunnan Baiyao as a strategic investor through a non-public offering of shares to support the company’s long-term business development, improve the industrial layout and enhance the company’s overall strength.